Quantcast
Last updated on April 17, 2014 at 16:09 EDT

Latest Fludeoxyglucose Stories

2009-05-27 07:29:30

 Non-invasive imaging can measure how well patients with the most common form of breast cancer - estrogen receptor positive type - respond to standard aromatase inhibitor therapy after only two weeks and shows similar findings that more invasive needle sampling identifies, according to a poster presentation to be presented at the ASCO annual meeting next week.Using Positron Emission Tomography (PET) scanning and a glucose analogue called FDG, a research team led by Hannah Linden, M.D....

2009-05-14 07:30:00

Comprehensive Phase 2 Program Combines Histology, Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of Action and Positive Impact on Vascular Inflammation SAN FRANCISCO, May 14 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed enrollment in a Phase 2 clinical trial of its lead drug, VIA-2291 in patients...

2009-04-07 14:41:00

Expanded Medicare coverage of PET scans improves access for patients to needed cancer diagnosis tool WAUKESHA, Wis., April 7 /PRNewswire-USNewswire/ -- GE Healthcare, a global leader in healthcare technology, supports the recent national coverage determination (NCD) from the Centers for Medicare and Medicaid Services (CMS), expanding coverage for initial testing with positron emission tomography (PET) for Medicare beneficiaries who are diagnosed with and treated for most solid tumor...

2009-03-26 09:30:00

Highlights Include Possis Acquisition and Patient Care Innovations WARRENDALE, Pa., March 26 /PRNewswire/ -- MEDRAD, INC.'s revenues grew to over $600 million in 2008, an increase of more than 10 percent over the previous year (excluding the effect of the Possis Medical, Inc. acquisition). A worldwide leading provider of diagnostic imaging and therapeutic medical devices, MEDRAD has achieved a double-digit annual revenue growth for over 10 years. (Logo:...

2009-03-16 07:00:00

New Omaha facility to help advance the early diagnosis and treatment of disease DUBLIN, Ohio, March 16 /PRNewswire-FirstCall/ -- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced that it has opened a new facility in Omaha, Neb. that manufactures radiopharmaceuticals, giving local physicians new tools that aid in the early diagnosis and treatment of disease. The new manufacturing facility, known as a...

2009-02-19 06:45:00

MOUNTAIN VIEW, Calif., Feb. 19 /PRNewswire/ -- Based on its recent analysis of the medical imaging market, Frost & Sullivan presents Naviscan, Inc. with the 2009 North American Frost & Sullivan Award for Emerging Technology of the Year. The Award recognizes the company's impressive progress in developing to market a next-generation, breast-specific PET scanner and adjunct biopsy guidance system that is set to redefine the standard of care for breast cancer patients. (Logo:...

2009-02-13 15:20:00

New technology reduces radiation exposure, eliminates workflow complexity, and enables patient-scheduling flexibility WARRENDALE, Pa., Feb. 13 /PRNewswire/ -- MEDRAD's Intego(TM) PET Infusion System has been named one of Medical Imaging Magazine's top eight most innovative products of the year. The magazine designated its top eight based on what its readership considers to be the most far-reaching, game changing or otherwise groundbreaking medical devices on the market. (Logo:...

2009-02-05 09:21:09

Women with a rare form of aggressive breast cancer may benefit from a newer form of imaging that gives doctors a better idea of where the disease may have spread. Researchers from the University of Texas, M.D. Anderson Cancer Center in Houston used a combination of fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) to evaluate inflammatory breast cancers (IBC) in 41 women between the ages of 25 and 71. IBC, which accounts for about 1 percent to 3 percent of...

2009-01-26 06:00:00

BOSTON, Jan. 26 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced today that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, covering methods of imaging cardiovascular plaque formation using F18 labeled 2-fluorodeoxy-D-glucose (FDG). This patent, exclusively licensed from the Massachusetts General Hospital, provides FluoroPharma with additional patent claims...

2009-01-06 12:00:00

Controlled FDG Delivery Study Uses Intego(TM) PET Infusion System to Compare Techniques for Patient Management WARRENDALE, Pa., Jan. 6 /PRNewswire/ -- MEDRAD, Inc., has signed a research agreement with the University of Zurich to study dynamic PET imaging with the MEDRAD Intego(TM) PET Infusion System. The researchers will utilize MEDRAD's latest technology to more precisely control the radioactive dose delivered during PET imaging procedures. (Logo:...